Stephen L. Meninger, PharmD, MS, MBA

Alnylam Pharmaceuticals

Poster(s):

• D0485 - The Impact of Acute Hepatic Porphyria on Mental Health: Results From the Porphyria Worldwide Patient Experience Research (POWER) Study
  Tuesday, October 25, 2022

  10:00 AM – 12:00 PM ET

• D0486 - Changes in Acute Hepatic Porphyria Health Impacts Since Initial Diagnosis: Results From the Porphyria Worldwide Patient Experience Research (POWER) Study
  Tuesday, October 25, 2022

  10:00 AM – 12:00 PM ET